Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Gillrie, M. R., B. Renaux, E. Russell-Goldman, M. Avril, A. J. Brazier, K. Mihara, E. Di Cera, et al. 2016. “Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence.” mBio 7 (5): e01120-16. doi:10.1128/mBio.01120-16. http://dx.doi.org/10.1128/mBio.01120-16.

Published Version
doi:10.1128/mBio.01120-16

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407896

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Thrombin Cleavage of *Plasmodium falciparum* Erythrocyte Membrane Protein 1 Inhibits Cytoadherence

Mark R. Gillrie, Bernard Renaux, E. Russell-Goldman, Marion Avril, Andrew J. Brazier, Koichiro Mihara, Enrico Di Cera, Danny A. Milner, Jr., Morley D. Hollenberg, Joseph D. Smith, May Ho

Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada; Department of Physiology and Pharmacology and Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA; Center for Infectious Disease Research, Seattle, Washington, USA; Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, USA

**ABSTRACT** *Plasmodium falciparum* malaria remains one of the most deadly infections worldwide. The pathogenesis of the infection results from the sequestration of infected erythrocytes (IRBC) in vital organs, including the brain, with resulting impairment of blood flow, hypoxia, and lactic acidosis. Sequestration occurs through the adhesion of IRBC to host receptors on microvascular endothelium by *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1), a large family of variant surface antigens, each with up to seven extracellular domains that can bind to multiple host receptors. Consequently, antiadhesive therapies directed at single endothelial adhesion molecules may not be effective. In this study, we demonstrated that the serine protease thrombin, which is pivotal in the activation of the coagulation cascade, cleaved the major parasite adhesin on the surface of IRBC. As a result, adhesion under flow was dramatically reduced, and already adherent IRBC were detached. Thrombin cleavage sites were mapped to the Duffy binding-like 61 (DBL61) domain and interdomains 1 and 2 in the PfEMP1 of the parasite line IT4var19. Furthermore, we observed an inverse correlation between the presence of thrombin and IRBC in cerebral malaria autopsies of children. We investigated a modified (R67A) thrombin and thrombin inhibitor, hirugen, both of which inhibit the binding of substrates to exosite I, thereby reducing its proinflammatory properties. Both approaches reduced the barrier dysfunction induced by thrombin without affecting its proteolytic activity on PfEMP1, raising the possibility that thrombin cleavage of variant PfEMP1 may be exploited as a broadly inhibitory antiadhesive therapy.

**IMPORTANCE** *Plasmodium falciparum* malaria is the third leading cause of mortality due to a pathogen, with 214 million people infected and 438,000 deaths annually. The adhesion of *Plasmodium falciparum*-infected erythrocytes (IRBC) to microvascular endothelium is a major pathological process in severe malaria. While the recent implementation of artemisinin-based antimalarial therapy for severe malaria improves patient survival by targeting all parasite stages, antiparasite drugs alone may not immediately reverse pathophysiological processes in occluded vessels. Here we show that thrombin, an enzyme intimately involved in the clotting process, cleaves the main parasite adhesin expressed on the surface of IRBC, thereby preventing and reversing the binding of IRBC to endothelial cells. This beneficial effect of thrombin can be achieved by modified thrombins that cause significantly less clotting and vessel leakage while preserving the ability to cleave the parasite protein. Our results provide the basis for using modified thrombins as adjunctive therapy in severe malaria.

In the past 15 years, mortality due to the protozoan parasite *Plasmodium falciparum* has decreased by 60% globally (1), and this is largely attributed to the efficacy of antimalarial combination therapy that includes artemisinin derivatives (2, 3). The drug has a rapid parasiticidal action and targets all stages of the erythrocytic cycle of the parasite. Parasite clearance is usually achieved within the first 24 to 36 h after hospital admission, during which most of the deaths occur. Unfortunately, although not entirely unexpectedly, artemisinin-resistant parasites have now emerged in Southeast Asia, the hotbed of antimalarial resistance (4). Moreover, resistance has spread to some of the drugs that are used in combination with artemisinins—e.g., piperaquine (5). There is therefore an urgent need to develop an adjunctive therapy that is directed toward major pathogenic processes rather than focusing solely on the elimination of parasites.

One target for adjunctive therapy is the sequestration of *P. falciparum*-infected erythrocytes (IRBC) in the microcirculation of vital organs, leading to impairment of blood flow, hypoxia, and lactic acidosis (6). Sequestration results from the adhesion, or cytoadherence, of IRBC to vascular endothelial cells, and the process is mediated by the variant parasite ligand *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) and endothelial receptors, of which a number have been implicated in severe disease (7, 8). Evidence for cytoadherence as a major pathological process...
comes not only from detailed histopathological studies of human postmortem tissues (9, 10) but also from imaging the microcirculation in infected patients (11), as well as clinical studies showing decreased cerebral perfusion (12) and lactate production (13) in patients with severe falciparum malaria. The importance of cytoadherence is supported further by the increased prevalence of protective point mutations in the hemoglobin gene within human populations living in areas where malaria is endemic: e.g., hemoglobin C and hemoglobin AS. The protection is due at least in part to an abnormal display of PfEMP1 on the surface of IRBC, which profoundly affects their ability to adhere to endothelial cells (14, 15). These observations clearly indicate that reducing cytoadherence is a therapeutic option for improving clinical outcomes.

In pediatric patients with cerebral malaria (CM), coagulopathy leading to fibrin deposition may also be a contributing factor to disease severity (16). Specifically, adherent IRBC have been shown to induce tissue factor (TF) production by endothelial cells in vitro, thus initiating the extrinsic coagulation pathway (17). Activation of the intrinsic pathway is also found in adult patients with severe malaria (18) and can be initiated in vitro by the release of the contents of the parasite digestive vacuole (19). Moreover, the secreted parasite product Plasmodium falciparum histidine-rich protein (PfHRP-2) contributes to a procoagulant environment by inhibiting the activity of antithrombin III (20), and the endothelial protein C receptor (EPCR)-binding cysteine-rich interdomain region of PfEMP1 inhibits the generation of activated protein C (APC) (21, 22), a key anticoagulant protein. These in vitro observations and the demonstration of fibrin deposition in >85% of cerebral microvessels in children who died from cerebral malaria (16) make a strong case for the potential pathological significance of microvascular thrombosis in pediatric cerebral malaria.

Central to the interplay between the malaria parasite and the human coagulation system is the serine protease thrombin, which directly coordinates the balance between a procoagulant state by fibrin generation and an anticoagulant state by the activation of protein C. Additionally, depending on the site of substrate cleavage, thrombin can induce either cytoprotection of endothelial barrier function or proinflammatory effects and barrier dysfunction through activation of protease-activated receptor-1 (PAR1), -3, and -4 signaling (23). Recognition of substrates such as fibrinogen and PAR1 requires extensive interactions with the active site and exosite I on thrombin (24).

In previous experiments with the parasite lines IT4var19 and IT4var07 (21), we observed that the exposure of endothelial cell-parasite cocultures to thrombin led to the detachment of IRBC from primary human brain and lung microvascular endothelial cells (M. R. Gillrie et al., unpublished data). The observation suggested a previously unappreciated proteolytic activity of thrombin on either endothelial receptors or PfEMP1. In this study, we present functional and biochemical findings to demonstrate cleavage of multiple PfEMP1 variants by thrombin. Engineered thrombins with minimal PAR1 activation but preservation of the proteolytic activity against PfEMP1 may serve as a potential adjunctive approach for severe malaria.

RESULTS

Thrombin inhibits IRBC adhesion to microvascular endothelial cells under shear stress. To investigate if thrombin has any intrinsic effect on IRBC, the adhesion of diverse P. falciparum binding phenotypes to endothelial cells was studied in a parallel-plate flow chamber using four previously characterized IT4 laboratory-adapted parasite lines that express a single predominant var gene: derived from the parental parasite lines FCR3/IT4 and HB3. Each var gene is composed of a cysteine-rich interdomain region (CIDR) and Duffy-binding like (DBL) domains. B (to E) Adhesion of IRBC from IT4-derived parasite lines pretreated with 10 nM thrombin with or without 100 nM hirudin for 30 min at 37°C. Adhesion assays on HLMEC or HDMEC were performed using IRBC at 1% hematocrit and 4 to 5% parasitemia to microvascular endothelial cells (21), while the parasite lines IT4var07, which adhere to EPCR, were tested on primary human lung microvascular endothelial cells (HLMEC) (21), while the parasite lines IT4var01 and IT4var11 and clinical parasite isolates expressing phenotypes to endothelial cells was studied in a parallel-plate flow chamber using four previously characterized IT4 laboratory-adapted parasite lines that express a single predominant PfEMP1 (25, 26) (Fig. 1A). The parasite lines IT4var19 and IT4var07, which adhere to EPCR, were tested on primary human lung microvascular endothelial cells (HLMEC) (21), while the parasite lines IT4var01 and IT4var11 and clinical parasite isolates that preferentially bind to CD36 (27) were tested on primary human dermal microvascular endothelial cells (HDMEC). IRBC were preincubated with 10 nM thrombin with or without the highly specific thrombin inhibitor hirudin (100 nM) for 30 min at...
Thrombin Cleaves PfEMP1

Thrombin cleaves PfEMP1 from the surface of P. falciparum IRBC. The inhibition of IRBC binding under shear stress by thrombin, a serine protease, suggests the IRBC adhesin PfEMP1 might be proteolytically cleaved by thrombin. The cleavage of PfEMP1 by 5, 10, and 50 nM thrombin was demonstrated by flow cytometry using a polyclonal antibody that targets the Duffy binding-like α2 (DBLα2) domain of IT4var19 (Fig. 2A to C). While PfEMP1 cleavage was 100% at 50 nM thrombin, there were consistent drops in mean fluorescent intensity (MFI) of 50 and 75% for PfEMP1 expression at 5 and 10 nM thrombin, respectively. Thrombin did not induce any morphological changes in IRBC as examined by confocal fluorescence microscopy, but consistent with the flow cytometry results, there was a loss of punctate staining by anti-DBLα2 (Fig. 2D). Similarly, cleavage of surface PfEMP1 of the parasite line IT4var07 was demonstrated by flow cytometry using a var-specific polyclonal antibody (Fig. 2E). In contrast, no cleavage of the PfEMP1 of the parasite line HB3var03 (Fig. 1A) by thrombin was seen (Fig. 2F), consistent with the lack of effect of thrombin on the adhesion of this parasite line to an immortalized brain microvascular endothelial cell line (THBMEC) in a static binding assay (29) (Fig. 2G). This parasite line was tested in a static binding assay as it did not adhere well to HLMEC under flow conditions (<10 adherent IRBC/mm²). These results demonstrate that not only does thrombin functionally impair IRBC adhesion to endothelial cells, it likely does so by directly cleaving the primary parasite adhesin PfEMP1.

Thrombin cleaves PfEMP1 of IT4var19 at DBLδ1 and inter-domains 1 and 2. To determine potential thrombin cleavage sites within PfEMP1 proteins, we performed a detailed search of 30 published var gene sequences with partially defined binding phenotypes using the algorithms Prosper (30) and ExPasy Peptide Cutter (31), which are highly specific (>95%) but not sensitive (<70%) for thrombin cleavage sites. Neither algorithm revealed a potential thrombin cut site in IT4var19 PfEMP1, but they did demonstrate 34 potential cut sites in 14 of the remaining 29 var genes (Table 1). We also performed more sensitive but less-specific manual searches of the protein sequences for proline-arginine (PR) and more specifically the PRXXR sequence that has been reported as a preferred site for thrombin activity (32). This search revealed a large number of PR sequences both within particular PfEMP1 DBL and CIDR domains as well as in the interdomain regions. However, the only potential thrombin cleavage site fulfilling the PRXXR sequence requirements of IT4var19 was a relatively conserved PRRR sequence in the DBLδ1 domain (Fig. 3A). Interestingly, for the five parasite lines tested in this study, the presence of the PRRR sequence in the DBLδ1 domain predicted the ability of thrombin to inhibit adhesion (Table 1).

Thus, thrombin did not affect adhesion of the two parasite lines that do not express the thrombin-susceptible DBLδ1 sequence (IT4var01 and HB3var03).

The presence of the PRRR sequence within the highly conserved homology box 4 and frequently found DBLδ1 domain suggests that this candidate cleavage site is likely common to a large number of var genes (33). To investigate whether the PRRR sequence of DBLδ1 of IT4var19 was targeted by thrombin for cleavage, we synthesized the peptide CVPPRRRLYY (amino acids [aa] 1768 to 1778) and subjected it to high-performance liquid chromatography/matrix-assisted laser desorption ionization (HPLC/MALDI) analysis after exposure to thrombin. The results showed that thrombin cleaved the synthetic peptide after arginine 1772 (CVP RRRLYY), confirming that the PRRR sequence is a possible target of the proteolytic activity of thrombin (Fig. 3B). To confirm cleavage of DBLδ1, we also subjected the entire recombinant IT4 var19 DBLδ1 domain to thrombin cleavage followed by matrix-assisted laser desorption (MALDI) identification of the resulting proteolytic fragments. Exposure of full-length DBLδ1 to thrombin demonstrated a minor cleavage at arginine 1772 (PPR/R) and a major cleavage site at 1774 (PPRR/R) (Fig. 3C), both of which cleavage products were not found when thrombin was inhibited by hirudin (Fig. 3D). Both cleavage sites were within the predicted PRRR sequence and the former confirmed the cleavage site found within the synthetic peptide (Fig. 3B). Thrombin did not cleave recombinant DBLδ6 domain from IT4var19 that was included as a negative control (Fig. 3E).

To determine the potential global relevance of the PRRR cleavage sites, we manually analyzed all published var genes from seven published parasite genotypes for the presence of PRRRRLY. For each var gene, we ascertained the var group, presence of DBLδ1, and predicted binding phenotype (33) (see Table S1 in the supplemental material). Our search revealed that 135 of 368 var genes from P. falciparum contained the PRRRRLY sequence. Of the 135 P. falciparum var genes, 130 contained a DBLδ1 with nearly all PRRRRLY sequences found within this domain. Of those var gene products containing the sequence in question, 11% had an UpsA promoter, 59% were UpsB, and 30% were UpsC, compared to 19% UpsA, 60% UpsB, and 21% UpsC var genes across the seven parasite genotypes, excluding the var LCSA pseudogene and the atypical type 3 var gene. The predicted binding phenotypes based on the CIDR1 domain type revealed 85% were CD36 binders (CIDRα2 to -6), 11% were EPCR binders (CIDRα1), and 4% (non-CIDRα) had an unknown binding phenotype, similar to their representation in the 3D7 genome reference isolate (84%, 11%, and 5%) (34). This suggests that although prevalent in 37% of all var genes, there is no selection bias for the PRRRRLY cleavage site between different var groups or binding phenotypes (Table 1; see Table S1).

We next focused on the most likely cut sites in the remaining extracellular IT4var19 protein selected manually from the four relatively short interdomain sequences (54 to 91 aa) as these sequences are predicted to have little secondary structure and would be accessible to thrombin (highlighted in Fig. 4A). Five highly purified (>95%) synthetic peptides from all four of the interdomains were incubated with thrombin for 30 min to 2 h, and the amounts and sites of cleavage were determined by HPLC and MALDI analysis (Fig. 4B to F). A positive-control peptide derived from the consensus thrombin cut site in PAR4 (35) cleaved at the expected site (Fig. 4E). Major cleavage of inter-
domain 1 following arginine 1236 (KPR/GPAS) and minor cleavage of interdomain 2 following arginine 1665 (GLGR/SL) were noted. No cleavage was found in the remaining peptides from domains 3 and 4.

Blockade of thrombin exosite I reduces thrombin-induced endothelial permeability but preserves PfEMP1 cleavage. The binding of substrates to thrombin and subsequent proteolysis are based on specific interactions with the active site, exosites I and II,
TABLE 1 Analysis of *P. falciparum* var genes with partially defined binding phenotypes for the presence of thrombin cleavage sites

| var gene type<sup>a</sup> | Genome | Geographic origin | Binding phenotype | No. of potential thrombin cleavage sites by<sup>b</sup> | No. of potential thrombin cleavage sites with sequence<sup>c</sup> | Presence of<sup>d</sup> | Thrombin cleavage |
|--------------------------|--------|------------------|------------------|-----------------------------|-----------------------------|------------------|------------------|
| IT4var06 (DC8) | IT4/FCR3 | Southeast Asia | EPCR | 0 | 11 | 7 | 1<sup>d</sup> | Yes | No | No | ND<sup>e</sup> |
| IT4var19 (DC8) | IT4/FCR3 | Southeast Asia | EPCR | 0 | 0 | 7 | 1<sup>d</sup> | Yes | Yes | Yes | ND |
| IT4var20 (DC8) | IT4/FCR3 | Southeast Asia | EPCR | 0 | 1 | 7 | 0 | Yes | No | No | ND |
| IT4var32b (DC8) | IT4/FCR3 | Southeast Asia | EPCR | 0 | 0 | 7 | 1<sup>d</sup> | Yes | Yes | Yes | ND |
| DD2var47 (DC8) | DD2 | Southeast Asia | EPCR | 0 | 1 | 6 | 0 | Yes | No | No | ND |
| IGHvar19 (DC8) | IGH | India | EPCR | 0 | 0 | 6 | 1<sup>d</sup> | Yes | No | No | ND |
| RAJ116var8 (DC8) | RAJ116 | India | EPCR | 0 | 0 | 4 | 0 | No | No | No | ND |
| PFCLINvar30 (DC8) | PFCLIN | Africa | EPCR | 0 | 0 | 4 | 0 | No | No | No | ND |
| PF00020c (DC8) | 3D7 | Unknown | EPCR | 0 | 2 | 10 | 2 | Yes | No | No | ND |
| PF08_0140 (DC8) | MAL6P1.316 (DC8) | 3D7 | Unknown | EPCR | 0 | 1 | 6 | 0 | No | No | No | ND |
| RAJ116var11 (DC8) | RAJ116 | India | EPCR | 0 | 0 | 6 | 1<sup>d</sup> | Yes | No | No | ND |
| PFCLINvar31 (DC8) | PFCLIN | Africa | EPCR | 0 | 2 | 1 | 1 | Yes | No | No | ND |
| MALE6P1.316 (DC8) | 3D7 | Unknown | EPCR | 0 | 1 | 6 | 0 | No | No | No | ND |
| IT4var67 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 0 | 3 | 0 | Yes | No | Yes | ND |
| IT4var13 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 0 | 3 | 0 | Yes | No | Yes | ND |
| IT4var14 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 0 | 7 | 1<sup>d</sup> | Yes | No | No | ND |
| IT4var16 | IT4/FCR3 | Southeast Asia | CD36 | 1 | 2 | 4 | 1<sup>d</sup> | Yes | Yes | No | ND |
| IT4var31 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 0 | 3 | 1 | No | No | No | ND |
| IT4var33 | IT4/FCR3 | Southeast Asia | CD36 | 1 | 1 | 2 | 0 | Yes | No | Yes | ND |
| IT4var35 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 0 | 3 | 1<sup>d</sup> | Yes | No | No | ND |
| IT4var37 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 0 | 4 | 1<sup>d</sup> | Yes | No | No | ND |
| IT4var67 | IT4/FCR3 | Southeast Asia | CD36 | 0 | 3 | 3 | 1<sup>d</sup> | Yes | Yes | Yes | ND |
| HR3 | HR3 | Central America | EPCR | 0 | 0 | 5 | 1 | No | No | No | No |
| PF1235wD4 | 3D7 | Unknown | EPCR | 0 | 1 | 8 | 2 | Yes | No | Yes | ND |
| IT4var02 | IT4/FCR3 | Southeast Asia | ? | PECA1 | 0 | 0 | 8 | 1 | No | No | No | ND |
| PF11_0008 | 3D7 | Unknown | ? | PECA1 | 0 | 0 | 8 | 1 | No | No | No | ND |
| PF13_0003 | 3D7 | Unknown | ? | Rosette | 0 | 1 | 10 | 1 | No | No | No | ND |
| HR3var06 | HR3 | Central America | ? | Rosette | 0 | 0 | 6 | 0 | No | No | No | ND |
| IT4var09 | IT4/FCR3 | Southeast Asia | EPCR | 0 | 0 | 4 | 1<sup>d</sup> | Yes | No | Yes | ND |
| IT4var69 | IT4/FCR3 | Southeast Asia | ? | Rosette | 0 | 0 | 6 | 0 | No | No | No | ND |
| Total (n = 30) | | | | 8 | 26 | 170 | 23 | 18 | 2 | 3 | 3/5 |

<sup>a</sup> Thirty var genes encoding unique PfEMP1 were selected for comparison based on (i) being closely related to IT4var19 (domain cassette 8 [DC8] var genes—i.e., var genes with DC8 [NTS-DBL2-CDR1-DBL612-DBL646]), (ii) having partially defined binding phenotypes, and (iii) having available sequence data that were previously catalogued.

<sup>b</sup> The Prosper and Peptide Cutter algorithms or manual searches of PR sequences (PR or PRXXR) were performed to identify potential thrombin cleavage sites.

<sup>c</sup> The presence of DBL61 containing PRRRR or interdomain KPRGPA and GLGRSL sequences was also determined.

<sup>d</sup> PRRRR sequence within a DBL<sup>c</sup>. The presence of DBL<sup>b</sup>: Presence of DBL<sup>b</sup>. The Prosper and Peptide Cutter algorithms or manual searches of PR sequences (PR or PRXXR) were performed to identify potential thrombin cleavage sites.

<sup>e</sup> ND, not determined.

and the presence of cofactors such as thrombomodulin which block the procoagulant exosite I of thrombin and mediate a switch in substrate preference (36). To further define the interaction between PfEMP1 and thrombin, the effect on cleavage of PfEMP1 from IT4var19 by two modified thrombins was studied. R67A-thrombin has a mutation at exosite 1, while W215A E217A-thrombin (WE-thrombin) has mutations in the terminal segment of the thrombin active site (37). PfEMP1 cleavage in response to the modified thrombins was monitored by flow cytometry, while endothelial permeability induced by the modified thrombins was determined as a reduction in transendothelial resistance (TER) measured by electric cell-substrate impedance sensing (ECIS). We found that R67A-thrombin at 10 and 50 nM had the same dose-dependent proteolytic effect on PfEMP1 of IT4var19 as thrombin (Fig. 5A to C). As a result, R67A-thrombin completely inhibited IRBC adhesion under flow conditions (Fig. 5D), while the effects on endothelial resistance (Fig. 5E) and disruption of the junctional protein VE-cadherin were reduced by 65% compared to thrombin (Fig. 5F and G). In contrast, WE-thrombin of up to 50 nM did not cleave IT4var19 PfEMP1 (Fig. 5B), did not inhibit IRBC adhesion (Fig. 5D), and had no effect on permeability (Fig. 5E) or junctional protein expression (Fig. 5F and G).

We also tested the effect of a small sulfated peptide, hirugen (hirudin 54-65), that blocks exosite I on thrombin (38). In the presence of 1 and 5 μM hirugen, concentrations that do not inhibit endothelial APC generation (39), PfEMP1 cleavage was reduced by 45% and 40%, respectively, compared to thrombin alone (Fig. 6A and B). However, the reduction in ligand expression compared to untreated IRBC was sufficient to reduce adhesion of IRBC under flow conditions by 81% ± 0.3% (n = 3) (Fig. 6C). Hirugen at 1 μM also inhibited thrombin-induced permeability by 49% ± 7% (n = 3; P = 0.013), while at 5 μM, the inhibition of thrombin activity on permeability (Fig. 6D) and disruption of VE-cadherin expression (Fig. 6E) were complete.

**Wild-type thrombin and R67A-thrombin but not hirugentreated or WE-thrombin detach adherent IRBC.** To determine if thrombin could detach already adherent IRBC, IRBC of IT4var19 were allowed to adhere for 1 h to a monolayer of HLMEC prior to the addition of 5 or 10 nM thrombin for 30 min and 2 h. After nonadherent IRBC were removed by gravity sedimentation, the number of adherent IRBC per 100 endothelial cells (EC) was quantified. The results showed a time- and concentration-dependent effect of thrombin. The number of adherent cells was significantly reduced by 55% ± 6% and 94% ± 3% following incubation with 10 nM thrombin for 30 min and 2 h, respectively (n = 4; P = 0.024 and 0.018) (Fig. 7A and B). The near
total absence of adherent IRBC on the monolayers after 2 h of thrombin treatment is consistent with both the detachment of already adherent IRBC and inhibition of further adhesion. The effect of thrombin was completely abrogated by preincubation with 100 nM hirudin. Similar effects were shown between wild-type thrombin and R67A-thrombin at 10 nM but not WE-thrombin at 50 nM (Fig. 7C). In contrast, pretreatment of thrombin with hirugen inhibited its ability to detach IRBC under flow conditions (Fig. 7D). The discrepancy between the effect of hirugen on adhesion under flow (Fig. 6C) and the reversal of binding studies done under static conditions (Fig. 7) could be due to the greater sensitivity of the flow adhesion assay to reductions in PfEMP1 expression.

To investigate whether thrombin may also cleave parasite adhesion receptors from the surface of endothelial cells, HLMEC were pretreated with 10 nM thrombin prior to a flow chamber assay. Thrombin did not modify surface levels of two known parasite cytoadhesion receptors, intercellular adhesion molecule 1 (ICAM-1) and EPCR (Fig. 7E). Conversely, the proinflammatory cytokine tumor necrosis factor alpha (TNF-α) led to a partial reduction of EPCR expression and an approximately 50-fold increase in ICAM-1 expression, as expected (Fig. 7E). Thrombin pretreatment of HLMEC also had no effect on IRBC adhesion under flow conditions (Fig. 7F).

**Presence of microvascular thrombin inversely correlates with IRBC sequestration in pediatric cerebral malaria.** Tissue factor production by endothelial cells has been shown to be induced at sites of IRBC adhesion (17), initiating the extrinsic coagulation pathway. To determine if thrombin is detectable in cerebral microvessels and whether the presence of thrombin bears any relationship to IRBC sequestration, sections of postmortem brain tissue were examined by immunohistochemistry (IHC). The study population was a previously defined convenience sample of pediatric patients representing low to high sequestration in an ongoing study aimed at defining the clinicopathological correlation of cerebral malaria (CM) (D. A. Milner, Jr., K. B. Seydel, and T. E. Taylor, unpublished data). The patient set was therefore not selected specifically for this study, nor was the inclusion or exclusion of cases dependent on any criteria related to the presence of thrombin and/or sequestration. CM was defined as the presence of IRBC or pigment clumps in >21% of cerebral microvessels (40). Two hundred randomly selected vessels from each of the 25 patients were scored for the presence or absence of thrombin and sequestered IRBC (Table 2). Representative images of Thr+/Seq−, Thr+/Seq−, Thr−/Seq−, and Thr−/Seq− vessels are shown in Fig. 8A to C.

Quantitation of the vessels from all 25 cases demonstrated thrombin staining alone in 14% (median) of cerebral microvessels (inter quartile range [IQR], 5 to 44%), IRBC alone in 25% (median; IQR, 12 to 61%) (Fig. 8D; Table 2). When the results were expressed as an odds ratio (OR), where any number that is <1.0 demonstrates an inverse correlation between sequestration and thrombin, the OR for all individual cases was less than 1, with the exception of 1 case (range, 0.02 to 0.45; P < 0.001 to 0.388). A similar finding was seen in the estimated OR. The summary statistic for all vessels showed an actual OR and estimated OR (eOR) of 0.40 and 0.41, with a CI value of 0.29 to 0.36; 95% confidence interval [CI], 0.29 to 0.36; P < 0.001) or all 25 cases (r_e = −0.20; 95% CI, −0.175 to −0.227; P < 0.001).

**DISCUSSION**

Thrombin, the pivotal molecule in fibrin clot and APC generation, is a highly selective serine protease with well-characterized human substrates involved in coagulation (factors V, VIII, XI, and XIII; protein C; and fibrinogen) or endothelial barrier function (PAR1,
The recent characterization of the thrombin consensus cleavage site of Pro–Arg–(Ala-Gly-Ser-Thr)–(not Asp-Glu)–Arg (PRXXR) has led to the prediction of numerous additional human thrombin substrates involved in cell adhesion (e.g., the integrin αvβ3), central nervous system development, and circulatory homeostasis (32). Among pathogens, only pallilysin from Treponema pallidum, the causative agent of syphilis, is known to be cleaved by thrombin from a proenzyme into an active met-

FIG 4 IT4var19 interdomains 1 and 2 are cleaved by thrombin. (A) Schematic of the IT4var19 interdomains with the full sequence of each domain (numbered 1 through 4). The sequences used to generate synthetic peptides for thrombin cleavage determination are indicated in boldface. (B to F) HPLC analysis of thrombin cleavage (25 nM) of the 5 peptides from IT4var19 interdomains. The fragments and cleavage sites (in boldface) corresponding to the HPLC peaks are indicated by arrows (n = 2). (G) Thrombin cleavage of protease-activated protein 4 (PAR4) was included as a positive control (n = 2). The molecular mass (Da) of each resulting fragment, as determined by TOF/TOF MS, is indicated above each peak.
alloprotease allowing the spirochete to degrade fibrin clots and propagate infection (41). To date, no studies have investigated the impact of thrombin on \textit{P. falciparum} sequestration, the key pathogenic process in severe malaria.

In this study, we demonstrate that at physiologically relevant concentrations, thrombin cleaves the IRBC cytoadherent ligand PfEMP1 from the surface of IRBC in a dose-dependent fashion and impairs their adhesion to microvascular endothelium under flow conditions or even detaches already adherent IRBC from endothelial monolayers \textit{in vitro}. Cleavage was complete at 50 nM thrombin, but the 75% reduction of PfEMP1 expression seen at 10 nM was sufficient to result in a functional change, an observation that implies that there may be a threshold required for the density of receptor and ligand molecules and/or avidity of

![Fig 5](image-url)

**Fig 5** Effect of modified thrombins R67A-thrombin and WE-thrombin on PfEMP1 expression and endothelial permeability. Flow cytometry analysis of PfEMP1 expression on IRBC of IT4var19 treated with (A) 10 nM wild-type (WT) thrombin and R67A-thrombin or (B) 50 nM WT, R67A-, and WE-thrombin for 30 min at 37°C. Results are representative of 2 experiments. (C) Immunofluorescence microscopy of PfEMP1 expression on live IRBC from panel A. Images were taken at ×600 magnification. (D) Effect of 10 nM R67A- and 50 nM WE-thrombin on IRBC adhesion in the flow chamber assay. Results are presented as mean ± standard deviation (SD) \((n = 2)\). (E) Changes in endothelial electrical resistance as monitored by the ECIS system in 3-day postconfluent HLMEC treated with 10 nM WT and R67A-thrombin and 50 nM WE-thrombin. Changes in resistance were monitored for 18 h at 37°C. A drop in electrical resistance was indicative of increased endothelial permeability. The results shown (from 0 to 3 h) are representative of 3 experiments. (F) Confocal immunofluorescence microscopy of HLMEC monolayers treated with 10 nM WT or R67A-thrombin or 50 nM WE-thrombin. Disruption of VE-cadherin expression and intercellular gap formation (indicated by white arrows) were induced by WT thrombin and to a much lesser degree by R67A-thrombin but not by WE-thrombin. Images are representative of 10 random fields examined at 600× in each of 2 independent experiments. (G) Quantification of microscopic changes seen in panel F. For each condition, three randomly selected microscopic fields at ×600 magnification were examined for the number of intercellular gaps of >5 μm in diameter and expressed as gaps × 10^2 per mm². The results shown are representative of 2 independent experiments.
receptor-ligand interaction to mediate adhesion, particularly under physiological flow conditions. Whether the reduction of expression/function is due to partial cleavage of PfEMP1 on some IRBC or a decrease in the absolute number of PfEMP1 molecules that were completely removed is not addressed by our data. The proteolytic effect is seen in laboratory-selected lines as well as clinical isolates. These results strongly suggest that thrombin cleavage is independent of the adhesive phenotype of the parasites, since both CD36 and EPCR binding parasite lines were sensitive to cleavage.

Using synthetic peptides and recombinant protein, we mapped putative thrombin cleavage sites to the DBL/H9254 domain and interdomains 1 and 2 in the IT4var19 PfEMP1. Cleavage of DBL81 that is proximal to most of the PfEMP1 domains would explain the near complete inhibition of adhesion on both HLMEC and HDMEC. The interdomain 1 and 2 cleavage sites may also contribute to the inhibition of adhesion, as they are both proximal to the semiconserved head structure that has been shown to mediate adhesion to multiple adhesion molecules (34). The true function of these interdomains is unclear, although they do contain conserved elements and are predicted to have low secondary structure (33), possibly rendering them accessible to serum proteases. However, it should be noted that the DBL81 and interdomain predicted cut sites on IT4var19 that we studied are by no means exhaustive, as we found an additional 34 high-probability cut sites using established algorithms in 13 of the remaining 14 var genes examined in Table 1 that represented parasites of diverse adhesive phenotypes. Therefore, more PfEMP1 variants than IT4var19 will need to be studied using native or full-length PfEMP1 to comprehensively identify the thrombin cleavage sites and to determine the kinetics and efficiency of the cleavage. The ultimate functional importance of potential thrombin...
bin cut sites is likely to depend on the location, abundance, affinity, and accessibility of the cleavage sequences to thrombin.

To further delineate the molecular interaction between PfEMP1 and thrombin, we tested the proteolytic activity of two modified thrombins toward PfEMP1. A schematic model is shown in Fig. 9. We found that the active site of thrombin is of critical importance as WE-thrombin has no proteolytic activity toward PfEMP1. This result is not unexpected in view of the compromised activity of this mutant except toward protein C in the presence of thrombomodulin (42). In contrast, R67A-thrombin has proteolytic activity toward PfEMP1 comparable to that of thrombin, suggesting that exosite I is not required for PfEMP1 cleavage. The lack of involvement of exosite I in PfEMP1 cleavage is supported by our results using hirugen, a competitive exosite I inhibitor. These results are noteworthy given that thrombin activity toward many physiological substrates in the proinflammatory

FIG 7 Thrombin detaches adherent IRBC from HLMC. (A) Detachment of adherent IRBC from HLMC monolayers following thrombin treatment (5 or 10 nM) of cocultures for 30 min at 37°C (n = 3). (B) Detachment of adherent IRBC from HLMC monolayers following thrombin treatment (5 or 10 nM) of cocultures for 2 h at 37°C (n = 4). (C) R67A- but not WE-thrombin detaches adherent IRBC. Results are shown as mean ± SEM (n = 3) and were analyzed by ANOVA followed by post hoc multiple comparisons using Tukey’s test. (D) Hirugen inhibited the effect of thrombin on detachment of adherent IRBC. Results are presented as mean ± SD (n = 2). (E) Thrombin treatment had no effect on ICAM-1 or EPCR expression. (F) Lack of effect on adhesion under flow conditions on HLMC pretreated with 10 nM thrombin for 30 min.
and coagulation cascades specifically requires exosite I and, to some extent, exosite II interaction. Any beneficial effect of thrombin that only depends on the active site opens significant opportunities in therapeutic intervention for severe malaria. Several thrombin mutants like R67A-thrombin have been engineered with compromised exosite I activity but normal activity toward chromogenic substrates that only bind to the active site (37). R67A-thrombin would be an attractive therapeutic candidate because it has 100-fold-reduced activity toward fibrinogen and coagulation cascades specifically requires exosite I and, to some extent, exosite II interaction. Any beneficial effect of thrombin that only depends on the active site opens significant opportunities in therapeutic intervention for severe malaria. Several thrombin mutants like R67A-thrombin have been engineered with compromised exosite I activity but normal activity toward chromogenic substrates that only bind to the active site (37). R67A-thrombin would be an attractive therapeutic candidate because it has 100-fold-reduced activity toward fibrinogen and PAR1 but only a10-fold-reduced activity toward protein C (37). Although R67A-thrombin binds to PAR1 with 105-fold-less affinity than native thrombin (43), and therefore would be ineffective as a competitive inhibitor to block endogenous thrombin activation of PAR1, it has been engineered to have limited proinflammatory activity while retaining selectivity for protein C activation, and as shown here, it retains potential PFPMP1 cleavage function. On the other hand, hirugen, a small molecule that inhibits substrates binding to exosite I as does R67A-thrombin, could shift the activity of endogenous thrombin toward beneficial effects. Hirugen was effective in ameliorating the disruptive effect of thrombin on endothelial barrier integrity while preserving sufficient proteolytic cleavage of PFEMP1 to inhibit adhesion under shear stress. It is interesting to note that the effect of hirugen on exosite I is similar to that of soluble thrombomodulin, which is currently undergoing clinical trials for the treatment of sepsis and disseminated intravascular coagulation (44). While antimalarial drugs kill parasites, they may not immediately reverse pathophysiological processes in occluded vessels. Therefore, we can envision combining modified thrombin-based approaches with antimalarial drugs to achieve both rapid parasite killing and release of sequestered IRBC.

Whether thrombin cleavage of PFEMP1 occurs in vivo remains to be determined. In the absence of an adequate animal model for P. falciparum sequestration, which would have allowed for the examination of PFEMP1 cleavage in the complex milieu of an acute infection, the presence of thrombin in cerebral microvessels and the inverse correlation with sequestration in pediatric CM autopsies suggest that thrombin could cleave PFEMP1 in vivo. The extent to which this process occurs would depend on the local thrombin concentration at the site of cytoadhesion and the shear stress in the microvessels, as well as the susceptibility of the particular PFEMP1 variants expressed by the parasite isolates. At sites of lower thrombin production, IRBC may be detached or prevented from adhering in the absence or presence of coagulation abnormalities. We in fact demonstrated that surface-expressed PFEMP1 on IRBC is cleaved by thrombin at a concentration that is far lower than the levels observed during fibrinogenesis in vivo (200 to 300 nM). This process may occur in patients who do not go on to develop severe disease and hence would not be examined at autopsy. Indeed, there is evidence that thrombin activation mark-

| Case no. | Diagnosisa | % PVb | No. of microvessels with thrombin/sequestrationc | OR | eORd | P valuee |
|----------|------------|-------|-----------------------------------------------|----|------|---------|
| 37       | CM1        | 26.2  | 14 186 1 0 0.04 0.075                         |
| 100      | CM1        | 37.0  | 19 103 25 53 0.39 0.40 0.005                  |
| 99       | CM1        | 60.9  | 7 36 58 99 0.33 0.37 0.007                    |
| 95       | CM1        | 84.9  | 0 9 51 140 0.27 0.066                        |
| 1        | CM1        | 85.4  | 26 74 78 22 0.10 0.10 <0.001                  |
| 96       | CM2        | 35.6  | 3 26 142 29 0.02 0.03 <0.001                  |
| 85       | CM2        | 43.1  | 0 13 132 55 0.03 0.03 <0.001                  |
| 36       | CM2        | 45.9  | 0 33 67 100 0.04 0.04 <0.001                  |
| 55       | CM2        | 48.1  | 0 25 65 110 0.06 0.06 <0.001                  |
| 78       | CM2        | 48.1  | 0 57 46 97 0.04 0.04 <0.001                  |
| 94       | CM2        | 51.3  | 1 12 54 133 0.21 0.37 0.083                   |
| 60       | CM2        | 53.3  | 0 10 44 146 0.30 0.078                        |
| 26       | CM2        | 56.3  | 1 27 13 159 0.45 0.81 0.388                   |
| 83       | CM2        | 63.1  | 1 44 60 95 0.04 0.07 <0.001                   |
| 32       | CM2        | 77.2  | 0 28 29 143 0.17 0.09 0.009                   |
| 69       | CM2        | 80.7  | 0 1 138 61 0.22 0.310                        |
| 35       | CM2        | 83.7  | 0 4 168 28 0.03 0.03 <0.001                   |
| 6        | CM2        | 85.7  | 2 4 145 49 0.17 0.21 0.044                   |
| 66       | CM2        | 87.7  | 1 120 20 59 0.02 0.05 <0.001                  |
| 98       | CM2        | 91.1  | 1 24 18 157 0.36 0.67 0.279                   |
| 28       | CM2        | 96.2  | 0 5 134 61 0.08 0.08 <0.004                   |
| 58       | CM3        | 4.3   | 6 190 2 2 0.03 0.04 <0.008                   |
| 31       | CM3        | 4.5   | 164 31 4 1 1.32 2.06 0.586                   |
| 7        | CM6        | 4.8   | 90 107 3 0 0.21 0.099                        |
| 10       | CM9        | 12.7  | 86 110 3 1 0.26 0.39 0.233                   |

Total: 422 1,279 1,500 1,800 0.40 0.41 <0.0001

a Diagnosis: CM1, sequestration only; CM2, sequestration and fibrin deposition; CM3, coma with no malarial pathology in brain; CM6, severe malarial anemia; CM9, pneumonia and incidental parasitemia.
b % PV is the percentage of parasitized cerebral microvessels in autopsy tissue sections used for diagnosis of CM (40).
c Two hundred microvessels from each patient were scored for the presence of thrombin, sequestration (IRBC), neither, or both.
d Cells with 0 counts made the odds ratio (OR) for those samples impossible to calculate. Estimated OR (eOR) were computed by adding 1 to all cells with a 0 count.
e Boldface P values are <0.05.
ers, including d-dimer and fibrin degradation products, are significantly elevated in uncomplicated malaria compared to healthy controls (45). At sites of higher thrombin production, thrombin cleavage sites may have been retained in the highly variant PfEMP1 family as a “steam valve-like” mechanism to release sequestered IRBC. This would favor host survival and parasite transmission. However, thrombin activation also leads to the generation of excessive coagulation factors that are important mediators of inflammation, as well as promoting microvascular thrombosis. In addition, the activation of PAR1 by thrombin results in the generation of proinflammatory cytokines and disruption of barrier integrity. These detrimental effects of thrombin will contribute to the pathology of severe malaria in addition to its effect on sequestration. This scenario is similar to that with a number of inflammatory mediators, such as tumor necrosis factor, which at low levels may be beneficial to the host in stimulating innate immune responses. However, an uncontrolled or exaggerated cytokine response would lead to immunopathology and demise of the host. This makes our proposed therapy with modified thrombins (R67A) and thrombin modulators (hirugen) attractive as they can serve to shift thrombin cleavage events toward protein C activation and away from PAR1 and fibrinogen activation, while both preserve the ability to cleave PfEMP1.

Our proposal is not entirely in contrast to that of Moxon et al. (16), who reported a correlation between high levels of thrombin and disease severity and the colocalization of thrombin clots with sequestered IRBC in cerebral microvessels. In the Moxon study, circulating levels of thrombin were deduced from the thrombin/antithrombin III (TAT) complex. As the complex is inactive, this measure may more accurately reflect cumulative thrombin production rather than active thrombin at a given time point. The level of circulating thrombin may also be different from that at a local site. Among the 25 patients in our convenience samples, a significant number of cerebral microvessels (median, 30%) had both IRBC and thrombin and, presumably, fibrin clots. An additional confounding factor is the possibility that IRBC with cleaved PfEMP1 may remain trapped within microvascular fibrin deposits. It should also be pointed out that fibrin deposition is not a universal feature of cerebral malaria. There is a subgroup of patients designated CM1 in whom sequestration occurs in the absence of fibrin clots. Taken together, these findings suggest a com-
plex interplay between cytoadherence, thrombin activation, and clot formation in vivo that may not be completely explained by autopsy findings.

To understand whether thrombin may modify parasite adhesion receptors on endothelial cells, the proteolytic effect of thrombin on endothelial receptors was examined. In preliminary experiments, adhesion of IT4var19 to HLMEC monolayers preincubated with 10 nM thrombin for 30 min was not reduced, and thrombin had no effect on endothelial ICAM-1 or EPCR expression. However, whether higher doses of thrombin or longer duration would have a different effect on HLMEC and other microvascular endothelium remains to be determined. Wild-type thrombin has been reported to induce adhesion molecules such as P-selectin and ICAM-1 on human umbilical vein endothelial cells within 15 to 30 min (46). As well, other molecules involved in cell adhesion and parasite binding are now predicted to be thrombin substrates (e.g., integrins [47]), so that the modulation of their expression by thrombin will also need to be determined. Based on the finding that all 7 recombinant IT4var19 DBL or CIDR domains bind to different types of microvascular endothelial cells via many as yet unidentified receptor molecules (26), targeting specific endothelial receptors would appear to be a very complex and perhaps unattainable goal compared to targeting a relatively common proteolytic cleavage site in the variant parasite adhesin family. More importantly, what we observed for thrombin may be a broader phenomenon involving other serum proteases that are increased in patients with severe malaria (16, 48). Our study suggests that modified thrombins may constitute a new approach to antiadhesive therapy.

**MATERIALS AND METHODS**

**Ethics statement.** Cryopreserved clinical parasite isolates obtained from adult Thai patients with acute falciparum malaria were obtained at the Hospital for Tropical Diseases, Bangkok, Thailand (27). The collection of specimens was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University. Informed consent was obtained from all patients and/or relatives according to the Declaration of Helsinki. Autopsy specimens from patients with cerebral malaria and noncerebral controls were obtained in an ongoing study (D.A.M.) focused on understanding the dynamics of sequestration. The study was approved by the ethics committees at the University of Liverpool, Michigan State University, and the University of Malawi College of Medicine. Informed consent was obtained from all patients and/or relatives according to the Declaration of Helsinki. Discarded human foreskins were collected for the isolation of endothelial cells for this study with written informed consent of the donors with their written informed consent. Both protocols were reviewed and approved by the Conjoint Ethics Board of Alberta Health Services and The University of Calgary, Alberta, Canada.

**Tissue culture and other reagents.** Unless otherwise specified, all tissue culture reagents were obtained from Invitrogen Life Technologies Canada, Inc. (Burlington, ON, Canada), and chemical reagents were purchased from Sigma-Aldrich, Co. (St. Louis, MO). The thrombin inhibitor recombinant hirudin was purchased from Hyphen Biomed (Neuville-sur-Oise, France). The modified thrombins WE-thrombin and R67A-thrombin were produced and purified as described previously (36). Endothelial basal medium (EBM) and supplements were purchased from Lonza Group, Ltd. (Walkersville, MD).

**Parasites.** The parasite lines IT4var19, IT4var07, IT4var01, and IT4var11 were isolated from the parental strain IT4/25/5, as well as HB3var03 from HB3, by limiting dilution cloning (26). The expression of PfEMP1 in the five parasite lines was monitored by flow cytometry with var gene-specific polyclonal antibodies and/or var gene transcription profiling (25).

**Microvascular endothelial cells.** Primary human lung microvascular endothelial cells (HLMEC) were purchased from Lonza (21). Primary human dermal microvascular endothelial cells (HDMEC) were harvested and purified from discarded neonatal human foreskins (45). An immortalized brain endothelial cell line (THBMEC) was used (29).

**Flow chamber assay.** IRBC-endothelial cell interactions at fluid shear stresses approximating those in the microvasculature were studied using a parallel-plate flow chamber as described previously (27). Frozen aliquots of parasites were thawed and cultured for 24 to 30 h at 37°C and 95% N₂–5% CO₂ with RPMI plus 10% pooled human AB serum until the late trophozoite/early schizont stage as determined by light microscopy. Thawed parasites were used in experiments for 2 to 4 cycles, after which they were discarded. At the time of experimentation, a 1% IRBC suspension at 4 to 5% parasitemia pretreated with thrombin in serum-free medium for 30 min was infused over confluent HLMEC or HDMEC monolayers at 1 dyne/cm², which allowed for optimal visualization of the adhesive interactions in real time. Experiments were recorded and analyzed off-line. An adherent IRBC was defined as one that remained attached for >10 s. Results are expressed as the mean number of adherent IRBC/mm² in 4 randomly selected fields of view (200×) at the end of a 7-min infusion.

**Static binding and detachment assay.** Static binding assays for the parasite lines IT4var19, IT4var07, and HB3var03 on THBMEC were performed as described previously (29). For the detachment assay, IRBC at 1% hematocrit and 5 to 6% parasitemia in serum-free EB were allowed to adhere to monolayers of HLMEC on glass coverslips for 1 h at 37°C before the addition of 5 or 10 nM thrombin for 30 min or 2 h. Thrombin was added gently to the side of the chambers and allowed to slowly diffuse through the medium to avoid dislodging already adherent IRBC or activating endothelial cells. The coverslips were then washed by gravity. Air-dried and methanol-fixed coverslips were stained with Field stain, and the number of adherent IRBC under each experimental condition was quantified at a ×1,000 magnification by counting along the diameter of the coverslip (~300 to 400 endothelial cells). The data are expressed as the number of adherent IRBC/100 EC.

**Recombinant PfEMP1 protein/peptide synthesis and cleavage analysis.** Recombinant DBLβ1 and DBLβ6 domains from IT4var19 were generated as previously described (26). Peptides from IT4var19 interdomains, DBLβ1, and PAR4 were made by solid-phase synthesis on a Rink amide resin and purified to >95% by high-performance liquid chromatography (HPLC). One hundred micromoles of purified peptide or 5 μg recombinant protein was exposed to thrombin at 25 or 250 nM, respectively, for 30 min to 2 h at 37°C. Cleavage products were analyzed by HPLC and matrix-assisted laser desorption–ionization (MALDI) for peptide cleavage products or MALDI alone for recombinant protein cleavage products.

**Flow cytometry analysis of IRBC.** Trophozoite-stage IRBC of IT4var19, IT4var07, or HB3var03 were incubated for 45 min at 4°C with rabbit polyclonal antibody against the corresponding DBLβ domains specific to each var gene at a 1:20 dilution. Antibody labeling was detected with goat anti-rabbit IgG–Alexa 488 (Molecular Probes) at a 1:400 dilution for 30 min. Infected erythrocyte nuclei were detected with ethidium bromide (Invitrogen) at a 1:500 dilution added with the secondary antibody. Stained cells were washed in phosphate-buffered saline (PBS) and analyzed on an laser–fluorescence-activated cell sorter (FACS) machine (BD Biosciences). Analysis was performed using FlowJo 8 (Tree Star, Inc., Ashland, OR).

**Immunofluorescence microscopy of IRBC.** Live IRBC stained as described above for flow cytometry analysis were used to prepare blood smears on glass slides. Air-dried smears were fixed in ice-cold 90% acetone–10% methanol at −20°C for 10 min. Coverslips were mounted with ProLong Gold and imaged by wide-field immunofluorescence. Images were acquired using Openlab 5.0.2 (Improvision, Lexington, MA) on an
Gillrie et al.

Olympus IX70-SF2 inverted microscope (Center Valley, PA) using a cooled charge-coupled device (CCD) Retiga EXi camera from Q Imaging (Vancouver, BC, Canada). All images were taken with a 60× objective under oil immersion, where each field is equal to 224.2 by 170.8 μm (1,360 by 1,036 pixels).

**Confocal immunofluorescence microscopy.** Endothelial cells were seeded on gelatin-coated glass coverslips for characterization of junctions as previously described. All experiments were done at 48 to 72 h postconfluence with endothelial cells seeded at 5 × 10^5 cells/cm². A mononclonal anti-VE-cadherin antibody (2 μg/ml; clone F-8 [Santa Cruz Biotech, Dallas, TX]) was used for characterization of endothelial cell junctions. Alexa 488-labeled secondary antibody was added at 1:500 for an hour. After washing, the coverslips were imaged using an Olympus IX81 FV1000 laser scanning confocal microscope with 60× OPlanFLN oil objective NA 1.42 (Olympus Canada, Inc., Toronto, ON, Canada). Images were acquired at 800 by 800 pixels (212 μm by 212 μm) and 20 to 30 0.5-μm stacks at 2× Nvquist sampling using FV1000 acquisition software.

Image analysis was done using ImageJ v1.48 (NIH, Rockford, MD). Gaps in HLMEC were quantified by randomly selecting 3 microscopic fields for each condition in each experiment. A gap was defined as a single area larger than 5 fields for each condition in each experiment. A gap was defined as a single area larger than 5 μm in diameter devoid of cells (21). Results obtained from 2 independent experiments were expressed as gaps × 10^5 per mm².

**Endothelial resistance.** Real-time change in endothelial monolayer resistance as a measure of endothelial barrier function was determined using the ECIS system (Applied Biophysics, Troy, NY) according to the instructions of the manufacturer. In brief, 5 × 10^5 HLMEC were plated on a small gold electrode (well size, 0.8 cm²) precoated for 10 min with 10 μM l-cysteine. When the cells were 72 h postconfluent, the medium was changed to serum-free EBM and allowed to equilibrate for 2 h. Thrombin, modified thrombin, or thrombin with or without the inhibitors hirudin and hirugen was then added in 25-μl volumes. Changes in electrical resistance were monitored continuously for up to 18 h after the thrombin challenge.

**Brain histology and thrombin staining.** Immunohistochemical staining for thrombin was performed on 4-μm sections of formalin-fixed paraffin-embedded tissues by standard methods after antigen retrieval using a thrombin-specific monoclonal antibody (MAB) (clone 5G9 [Abcam]) at 1:100 dilution. Slides were counterstained with hematoxylin and were independently scored blind by two microscopists for the presence of thrombin (Thr) staining and/or sequestration (Seq), creating four categories of vessels: Thr+/Seq−, Thr+/Seq+, Thr−/Seq−, and Thr−/Seq+.

**Statistical analysis.** Statistical analysis of *in vitro* studies was performed using GraphPad Prism (version 6; GraphPad Software, Inc., La Jolla, CA). Data are expressed as the mean ± standard error of the mean (SEM) unless otherwise stated. All data were compared using analysis of variance (ANOVA) followed by post hoc multiple comparisons using Tukey’s test unless otherwise specified. Phi correlation (rφ) and odds ratio (OR) analysis were used for clinical data. *P* values of ≤0.05 were considered statistically significant.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01120-16/-/DCSupplemental.

**Table S1,** PDF file, 0.4 MB.

**ACKNOWLEDGMENTS**

We thank Carolyn Lane (Valley View Family Practice Clinic, Calgary, AB, Canada) for providing foreskin specimens for isolation of primary dermal microvascular endothelial cells and the Live Cell Imaging Facility, Snyder Institute for Chronic Diseases, University of Calgary, for the use of the confocal microscope and ECIS machine.

This work was supported by Canadian Institutes of Health Research grants MT14104 (M.H.) and MOP13759 (M.D.H.) and National Institutes of Health grants RO1 AI114766 (J.D.S.) and HL049413, HL073813, and HL112303 (E.D.C.). M.R.G., M.H., J.D.S., and M.D.H. conceived and designed the study. M.H., B.R., M.R.G., E.R.G., M.A., and M.K. performed experiments. M.R.G., M.H., M.D.H., and D.A.M. analyzed data. E.D.C. and A.I.B. provided reagents and expert advice. M.H., M.R.G., J.D.S., and M.D.H. wrote the manuscript.

None of the authors have any conflicts of interest.

**FUNDING INFORMATION**

This work, including the efforts of Joe Smith, was funded by HHS | National Institutes of Health (NIH) (RO1AI114766). This work, including the efforts of Enrico Di Cera, was funded by HHS | National Institutes of Health (NIH) (HL049413). This work, including the efforts of Enrico Di Cera, was funded by HHS | National Institutes of Health (NIH) (HL073813). This work, including the efforts of Morley D. Hollenberg, was funded by Gouvernement du Canada | Canadian Institutes of Health Research (CIHR) (MT14104). This work, including the efforts of Morley D. Hollenberg, was funded by Gouvernement du Canada | Canadian Institutes of Health Research (CIHR) (MOP13759).

**REFERENCES**

1. World Health Organization. 2015. World malaria report 2015. World Health Organization, Geneva, Switzerland.

2. Dondorp A, Nosten F, Stepnowska K, Day N, White N, South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. 2005. Artesunate versus quinine in treatment of severe falciparum malaria: a randomised trial. Lancet 366:717–725. http://dx.doi.org/10.1016/S0140-6736(05)6176-0.

3. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganal KD, Bojang K, Olasebikan K, Anunobi N, Maitland K, Kitaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kabuku C, Mtoge V, Nadjm B, Deen J, Mwanga-Amupariye J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mukolo OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyambo MA, Sakulthawg T, Ngum WP, Silamut K, Stepnowska K, Woodrow CJ, Bethell D, Wills B, Onoko M, Pete TE, von Seidell L, Day NP, White NJ, AQUAMAT Group. 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 367:1647–1657. http://dx.doi.org/10.1016/S0140-6736(10)61244-1.

4. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chhor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Iittamara P, Chotivanich K, Chutsattisak C, Suchatsouphon C, Runcharoen R, Stepnowska K, Guerlach PJ, Dondorp AM, Day NP, White NJ. 2014. Spread of artesinin resistance in Plasmodium falciparum malaria in Africa: a multisite prospective cohort study. Lancet Infect Dis 15:357–365. http://dx.doi.org/10.1016/S1473-3099(15)00487-9.

5. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. 2016. Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16:358–370. http://dx.doi.org/10.1016/S1473-3099(16)00497-X.

6. White NJ, Turner GD, Day NP, Dondorp AM. 2013. Lethal malaria: Marchiafava and Bignami were right. J Infect Dis 208:192–198. http://dx.doi.org/10.1093/infdis/jit116.

7. Rowe JA, Claessens A, Corrigan RA, Arman M. 2009. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells mechanisms and therapeutic implications. Expert Rev Mol Med 11:e16. http://dx.doi.org/10.1016/S1462399409001082.

8. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, Brazier AJ, Freeth J, Jespersen JS, Nielsen MA, Magistrado P, Lusingu J, Smith JD, Higgins MK, Theander TG. 2013. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature 498:502–505. http://dx.doi.org/10.1038/nature12216.

9. Silamut K, Phu NH, Whitty C, Turner GD, Louwrier K, Mai NT, Simpson JA, Hien TT, White NJ. 1999. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 155:395–410. http://dx.doi.org/10.1016/S0002-4940(10)65136-X.

10. Milner DA, Whitton RO, Kamiza S, Carr R, Liomba G, Dzamalala C, ...
Dondorp AM, Ince C, Charunwatthana P, Hanson J, Van Kuijen A, 11.

Petersen JE, Bouwens EA, Tamayo I, Turner L, Wang CW, Stins M, 23.

Ndonwi M, Burlingame OO, Miller AS, Tollefsen DM, Broze GJ, 17.

Francischetti IM, Seydel KB, Monteiro RJ, Whitten RO, Erexson CR, 17.

Dasari P, Heber SD, Beisele M, Torzewski M, Reifenberg K, Orning C, 15.

Moxon CA, Wassmer SC, Molyneux ME, Ward JM, Taylor TE 2007. Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimeric coagulation complexes. J Thromb Haemost 5:155–165. http://dx.doi.org/10.1111/j.1538-7836.2006.02232.x.

Choler a R, Brittain NJ, Gillirie MR, Lopera-Mesa TM, Diakite SA, Arie T, Krause MA, Guindo A, Tubman A, Fujioka H, Dia lou MO, Howard OK, Dia louo MO, Molyneux ME, Ward JM, Taylor TE 2007. Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimeric coagulation complexes. J Thromb Haemost 5:155–165. http://dx.doi.org/10.1111/j.1538-7836.2006.02232.x.

Choler a R, Brittain NJ, Gillirie MR, Lopera-Mesa TM, Diakite SA, Arie T, Krause MA, Guindo A, Tubman A, Fujioka H, Di a lou MO, Howard OK, Molyneux ME, Ward JM, Taylor TE 2007. Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimeric coagulation complexes. J Thromb Haemost 5:155–165. http://dx.doi.org/10.1111/j.1538-7836.2006.02232.x.

Celemns FR, Pramoolsinsap C, Lorenz R, Pukrittayakamee S, Bock HL, 28.

Gandhi PS, Chen Z, Di Cera E 2010. Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J Biol Chem 285: 15933–15938. http://dx.doi.org/10.1074/jbc.M110.115337.

Janes JH, Wang CP, Levin-Edens E, Vigan-Womas I, Guillote L, Melcher M, Mercereau-Puijalon O, Smith JD. 2011. The host binding specificity of the Plasmodium falciparum P f EMP1 protein family. PLoS Pathog 7:e1002032. http://dx.doi.org/10.1371/journal.ppat.1002032.

Avril M, Brazier AJ, Melcher M, Sampath S, Smith JD. 2013. DC8 and DC13 var genes associated with severe malaria bind avidly to diverse endothelial cells. PLoS Pathog 9:e1003430. http://dx.doi.org/10.1371/journal.ppat.1003430.

Thrombin Cleaves P f EMP1
Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I. 2013. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41:2069–2079. http://dx.doi.org/10.1097/CCM.0b013e31828e9b63.

45. Moxon CA, Chisala NV, Mzikamanda R, MacGormick I, Harding S, Downey C, Molyneux M, Seydel KB, Taylor TE, Heyderman RS, Toh CH. 2015. Laboratory evidence of disseminated intravascular coagulation is associated with a fatal outcome in children with cerebral malaria despite an absence of clinically evident thrombosis or bleeding. J Thromb Haemost 13:1653–1664. http://dx.doi.org/10.1111/jth.13060.

46. Sugama Y, Tiruppathi C, Offakidevi K, Andersen TT, Fenton JW, Malik AB. 1992. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. J Cell Biol 119:935–944. http://dx.doi.org/10.1083/jcb.119.4.935.

47. Davis SP, Lee K, Gillrie MR, Roa L, Amrein M, Ho M. 2013. CD36 recruits α5β1 integrin to promote cytoadherence of P. falciparum-infected erythrocytes. PLoS Pathog 9:e1003590. http://dx.doi.org/10.1371/journal.ppat.1003590.

48. Dietmann A, Helbok R, Lackner P, Issifou S, Lell B, Matsiegui P-B, Reindl M, Schmutzhard E, Kremsner PG. 2008. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. J Infect Dis 197:1614–1620. http://dx.doi.org/10.1086/587943.